Navigation Links
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
Date:4/29/2009

- Primary Endpoint met With a Significant Reduction in Relapse Rate

- Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression

- Submission for Registration of Cladribine Tablets Planned for mid-2009

SEATTLE and GENEVA, April 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, announced today detailed results of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The results of the pivotal trial show that annual short-course treatment with Cladribine Tablets led to a significant reduction in the rate of clinical relapses, disability progression and brain lesions, as well as a significant increase in the proportion of patients who remained relapse-free. The data were presented today for the first time, as a late-breaking oral presentation at the 61st Annual Meeting of the American Academy of Neurology (AAN) in Seattle, WA.

"All primary and secondary endpoints of the CLARITY study were statistically significant and demonstrate that annual short-course treatment with Cladribine Tablets in this study was effective across multiple important clinical and MRI efficacy measures," said Dr. Gavin Giovannoni, principal investigator of the study, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, United Kingdom.

"We are very pleased with the successful outcome of the CLARITY study," said Elmar Schnee, President of Merck Serono. "This is an exciting development in multiple sclerosis clinical research, and represents an important step towards delivering an oral therapy to people living with this condition."

The results from both Cladribine Tablets treatment groups in the study d
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today reported financial ... 2014.  Global revenue for the Company,s Urgent ... a new quarterly revenue record, as compared to $3.9 ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... one. You,re irritable, stressed out, and the cravings are intense. ... up and it isn,t your treadmill. But that,s exactly ... work trying to convince smokers to do. Dr. ... Laboratory, and his team (Dr. Anita Cramp, Dr. Mary Jung ...
... UC Irvine cardiologists have found a pouchlike structure inside ... source of stroke-causing blood clots. About 80 percent of ... due to blood clots blocking a brain artery. In up ... be determined. Study co-author Dr. Subramaniam Krishnan said the discovery ...
... have neurons dedicated to ,less than, ,greater than, problems, ... -- Monkey see, monkey do simple math? , A ... can engage in abstract mathematical reasoning using specific brain ... relationships. , The finding could provide insight into the ...
... ... manufacturer to moves its headquarters to a larger facility to better serve their customers. ... Farmingdale, NY ... supplements, along with Nutricap Labs, reputation for outstanding customer service, contributed to a rapid ...
... , Society Supports ... Studies That Compared Vertebroplasty to Placebo That Possibly Places ... , FAIRFAX, Va. , ... vertebroplasty -- a minimally invasive treatment performed by interventional ...
... , NEW YORK , Jan. 19 ... the operating efficiencies and service advantages of technology while reducing ... America (Guardian) , a leading provider of employee benefits for ... its self-service benefits website, Guardian Anytime. , Guardian,s campaign will ...
Cached Medicine News:Health News:Sweating out the cravings 2Health News:Monkey Brain 'Hardwired' for Simple Math 2Health News:Monkey Brain 'Hardwired' for Simple Math 3Health News:Nutricap Labs Energizes 2010 with Move to More Advanced GMP Certified Facility 2Health News:Society of Interventional Radiology Supports Treatment for Painful Spine Fractures: Patient Selection Key 2Health News:Society of Interventional Radiology Supports Treatment for Painful Spine Fractures: Patient Selection Key 3Health News:Society of Interventional Radiology Supports Treatment for Painful Spine Fractures: Patient Selection Key 4Health News:Society of Interventional Radiology Supports Treatment for Painful Spine Fractures: Patient Selection Key 5Health News:Society of Interventional Radiology Supports Treatment for Painful Spine Fractures: Patient Selection Key 6Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 3Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 4
Streptavidin MicroBeads are used for the indirect magnetic labeling and separation of cells, subcellular material, or bacteria labeled with a biotinylated primary antibody or ligand....
Malaria antibody EIA 480 test kit...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
Malaria Pf. Assay Range...
Medicine Products: